Electronic Acknowledgement Receipt				
EFS ID:	8185315			
Application Number:	10598535			
International Application Number:				
Confirmation Number:	6995			
Title of Invention:	Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production			
First Named Inventor/Applicant Name:	Piet Herdewijn			
Customer Number:	21559			
Filer:	Jan Tittel/Terese Miffitt			
Filer Authorized By:	Jan Tittel			
Attorney Docket Number:	50304/138001			
Receipt Date:	10-AUG-2010			
Filing Date:	01-SEP-2006			
Time Stamp:	10:48:05			
Application Type:	U.S. National Stage under 35 USC 371			

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	7195
Deposit Account	032095
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)	
1 NPL Documents	Examination_Report_549236. PDF	45030	no	1		
		ee4ba5713db5a10a0fdb23fc46f9b4072950 2eb7				
Warnings:						
Information:						
2 NPL Documents	Translation_Notification_Defec ts_Israel.PDF	84495	no	2		
		dc62051137ca06b3063f2c667940946bfb3a 64d7				
Warnings:						
Information:						
3 Transmittal Letter	IDS_Transmittal.PDF	54562	no	1		
		f87eb8926dae79786169c4d15db3d4ecc17 5d7b6				
Warnings:						
Information:						
Information Disclosure Statement (IDS) Filed (SB/08)	PTO_Form_1449_filed_August _10_2010.PDF	39489	no	1		
		786eac0192f5e975b137794cdc5734dc4c2 e06e7				
Warnings:						
Information:						
This is not an U	SPTO supplied IDS fillable form					
5 Fee Worksheet (PTO-875)	fee-info.pdf	30200	no	2		
		7ecaabec9312fbf733f9f38472e1ebb1648a 33ee				
Warnings:						
Information:						
	Total Files Size (in bytes)			253776		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.